This vaccine gives protection against tuberculosis TB infection. However, it is less effective in preventing the form of TB that affects the lungs. The BCG vaccine contains live bacteria that have been weakened attenuatedso that they stimulate the immune system but do not cause disease in healthy people.
PDF Cdc-pdf — k. Many foreign-born persons have been BCG-vaccinated. BCG is used in many countries with a high prevalence of TB to prevent childhood tuberculous meningitis and miliary disease.
Rates of protection against tuberculosis infection vary widely and protection lasts up to twenty years. Serious side effects are rare. Often there is redness, swelling, and mild pain at the site of injection.
Although far from perfect, the BCG vaccine is a relatively inexpensive, safe, and readily available vaccine that is still the only vaccine available for the prevention of human forms of TB. However the protection provided against pulmonary TB in adults is very variable. So the BCG vaccine is not generally given to adults. Not every country that could do so gives the vaccine to all children.
BCG vaccine contains a weakened form of the bacteria germ that cause TB. Because it is weakened it doesn't cause TB in healthy people but it helps develop some protection immunity against TB. BCG can also help prevent leprosy Hansen's Disease.
Despite significant advances in reducing mortality in recent decades through improved diagnosis and drug treatment regimens, in an estimated In addition to enormous human suffering, TB causes substantial economic burden and is one of the major drivers of global inequity. Whilst neonatal BCG vaccination is partially efficacious at protecting infants and young children, particularly from the most severe consequences of TB disease, it is poorly protective against pulmonary disease in adolescents and adults, and therefore at reducing Mtb transmission.
Information about tuberculosis TB disease, vaccines and recommendations for vaccination from the Australian Immunisation Handbook. Vaccination for certain groups of people is funded by states and territories. Tuberculosis is caused by the bacterium Mycobacterium tuberculosis.
A number of new tuberculosis TB vaccines have been or are entering clinical trials, which include genetically modified mycobacteria, mycobacterial antigens delivered by viral vectors, or mycobacterial antigens in adjuvant. Some of these vaccines aim to replace the existing BCG vaccine but others will be given as a boosting vaccine following BCG vaccination given soon after birth. It is clear that the existing BCG vaccines provide incomplete and variable protection against pulmonary TB. There is still a lot to learn about the BCG vaccine and the insights gained can help the development of more protective vaccines.
The protection, which some BCG vaccines could confer against the development of tuberculosis TB in childhood, might be indirectly reflected by the subsequent development of BCG immune response. The objectives of the study were to examine effectiveness and possible differences of post-vaccination reaction to a lyophilized BCG at different age groups and to evaluate its protection against TB in a decade's period. We studied the post-vaccination PPD-skin reaction and scar formation at three different school levels, corresponding to ages of 6, 12 and 15 years old, vaccinated by a lyophilized BCG vaccine Pasteur Institutecurrently used in our country.